Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system

Vedolizumab is the first gut-selective integrin blocker indicated for patients with Crohn's disease (CD) and ulcerative colitis (UC). This study aimed to examine the adverse events (AEs) profile of vedolizumab compared to anti-tumor necrosis factors (anti-TNFs) indicated for CD and UC using the...

Descripción completa

Detalles Bibliográficos
Autores principales: Cross, Raymond K., Chiorean, Michael, Vekeman, Francis, Xiao, Yongling, Wu, Eric, Chao, Jingdong, Wang, Anthony W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892509/
https://www.ncbi.nlm.nih.gov/pubmed/31800627
http://dx.doi.org/10.1371/journal.pone.0225572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892509/
https://www.ncbi.nlm.nih.gov/pubmed/31800627
http://dx.doi.org/10.1371/journal.pone.0225572

Ejemplares similares